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Abstract Background: Weight management is considered a key therapeutic strategy in
type 2 diabetesmellitus. However, little is known about the impact of weight loss
or body mass index (BMI) reduction on type 2 diabetes-related healthcare costs.
Objective: The aim of this study was to estimate the economic impact of
change in BMI among patients with type 2 diabetes mellitus from the Spanish
healthcare system perspective.
Methods: The ECOBIM study is an observational, non-interventional study
in which data on BMI change and costs incurred by patients with type 2
diabetes were collected cross-sectionally and retrospectively for a 12-month
period. Generalized linear mixed models were applied to estimate the effects
of (i) BMI change in general (one-slope model); (ii) BMI gain and no BMI
gain (two-slopemodel); and (iii) BMI gain and no BMI gain among obese and
non-obese patients (four-slope model).
Results: We studied 738 patients with a mean (SD) age of 66 (11) years and
BMI of 30.6 (5.2) kg/m2. During the 12-month study period, 41.2% of
patients gained BMI (BMI gainers) and 58.8% experienced either loss (52.2%)
or no change (6.6%) in BMI (non-BMI gainers). One-unit gain (or loss) in
BMI was significantly (p< 0.001) associated with a 2.4% cost increase (or
decrease) [one-slope model]. Every unit gain in BMI was associated with a
20.0% increase in costs among BMI gainers while losing one unit was associated
with an 8.0% decrease in costs among non-BMI gainers (two-slope model,
p< 0.01). The economic benefit associated with reducing one BMI unit was
9.4% cost decrease in obese and 2.7% in non-obese patients (4-slope model).
Conclusion: An increase in BMI among patients with type 2 diabetes was asso-
ciated with increased 1-year direct healthcare costs. A reduction in BMIwas asso-
ciated with appreciable short-term economic benefits, especially in obese patients.
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Key points for decision makers
 In Spanish patients with type 2 diabetes mellitus, increasing BMI was found to be associated
with increasing healthcare costs during the study period, and decreasing BMI with decreasing
costs, especially in obese patients
 Pharmacy costs were found to be significantly higher in type 2 diabetes patients who gained
BMI than in those without a BMI increase
Introduction
Type 2 diabetes mellitus is one of the leading
causes of morbidity and mortality in Europe.[1]
Currently, about 285million people worldwide
have diabetes and this number is expected to
reach 439million by 2030.[2] The prevalence of
diabetes mellitus in Spain is currently estimated
at 8.7%, and type 2 diabetes accounts for about
90% of cases.[3,4] Type 2 diabetes and its compli-
cations confer a substantial economic burden on
health systems and society that is expected to in-
crease as the prevalence of diabetes increases.[1,5,6]
In Spain, during 2002, the total direct medical
costs of type 2 diabetes have been estimated at
between h2.4 and h2.7 billion, which corresponds
to approximately 6.3–7.4% of total public health
expenditure.[7] Estimates of the mean type 2 dia-
betes annual direct costs in Spain are in the range
of h1290–h3009 per patient.[7-10]
Patients with type 2 diabetes are at increased
risk of cardiovascular disease owing to concomi-
tant presence of cardiovascular risk factors such
as obesity, hypertension, dyslipidaemia and to-
bacco use.[11] Obesity is the most significant risk
factor in the development of major complications
associated with type 2 diabetes.[12,13] According
to a recent estimate, 84% of patients with type 2
diabetes in Spain were either pre-obese, defined
by a body mass index (BMI) of >25 kg/m2 and
<30 kg/m2, or obese (BMI ‡30 kg/m2),[14] al-
though these estimations would be higher if body
composition techniques were considered a diag-
nostic tool.[15] The prevalence of type 2 diabetes
increases with the severity of obesity.[16,17]
Together, type 2 diabetes and obesity lead to a
higher incidence of diabetes-related complica-
tions and cardiovascular events,[18,19] which
translates into increased economic costs for na-
tional health systems.[1] Likewise, a very recent
study in diabetes patients with BMI ‡35 kg/m2
reported that clinical benefits of bariatric surgery
translated into considerable economic benefits.[20]
Furthermore, diabetes-related complications and/
or obesity adversely affect patients’ health-
related quality of life (HR-QOL),[21-24] primarily
in the physical domain. Although studies have
assessed the clinical benefit of weight loss in pa-
tients with type 2 diabetes,[25-27] little is known
about the impact of weight loss or BMI reduction
on type 2 diabetes care costs. The objective of the
present study was to estimate the effect of BMI
change in short-term economic costs of type 2
diabetes care from the Spanish healthcare system
perspective.
Materials and Methods
Study Design
The ECOBIM (Economic Impact of BMI on
Cost Associated with the Management of Patients
with type 2 Diabetes Mellitus) study was an ob-
servational, non-interventional, multicentre study
conducted in Spain. It consisted of a 12-month
observation period (study reference period) for
which data were collected retrospectively and
cross-sectionally from patients’ medical charts at
the study visit (figure 1). All data were provided
during usual care and no additional visits, tests or
interventions were required. The protocol was
approved byHospital Universitario La Paz ethics
committee (Madrid, Spain) and conducted in
accordance with the Spanish regulation for
observational studies and the Declaration of
Helsinki. Patients volunteered for the study and
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authorized the use of their data according to de-
fined provisions in Law 15/1999 of 13 December
on the Protection of Personal Data.
Study Population and Investigators
Patients included men and women aged
over 30 years who had been diagnosed with
type 2 diabetes by the investigator based on the
American Diabetes Association (ADA) criteria[4]
at least 24 months prior to their inclusion. Eligi-
ble patients had been followed during the normal
course of outpatient care, either in the hospital or
in the investigator’s private practice, and had
relevant information available in their medical
records for at least 24 months prior to study in-
clusion (information regarding weight was col-
lected [and used] from medical records 12, 18 and
24 months prior to the beginning of the study).
Patients were excluded if they had been diag-
nosed with type 1 diabetes mellitus or diabetes
secondary to other diseases, were female pa-
tients pregnant during the observation period,
or had participated in any other clinical study
24 months prior to the inclusion in the ECOBIM
study. Each site could recruit up to six patients
on consecutive days. For each day, the first
patient meeting the screening criteria and with
a scheduled visit during the study inclusion
period was included. Participating centres were
selected so that the geographic distribution and
investigator type (general practitioners and spe-
cialists) were representative of the physician
population treating patients with type 2 diabetes
in Spain.
Data Collection and Cost Assessment
At the study visit, sociodemographic, clinical
and healthcare resource utilization data related
to diabetes and its complications were collected
from the medical records for the 12-month study
reference period. Clinical data collected included
anthropometric characteristics, time since type 2
diabetes diagnosis, diabetes-related complications,
cardiovascular risk factors, glycaemic control
(glycosylated haemoglobin A1c [HbA1c], and fast-
ing plasma glucose [FPG]). Healthcare resource
data included visits to healthcare professionals
(primary care and specialist physicians, and other
professionals such as dieticians or podiatrists),
emergency room visits, hospitalizations, diabetes
treatment, other related co-morbidities, and use
of blood glucose monitoring strips.
The key variables were the change in BMI and
direct healthcare costs over the 12-month study
reference period. BMI was calculated from weight
and height measurements at the study visit and
from weight measurements at 12 – 1 months prior
to the study visit (the beginning of the study ref-
erence period). Healthcare costs were collected
over the same 12-month period. In order to avoid
under-reporting of healthcare resource usage
(based on medical record data), patients were
asked several questions during the study visit re-
garding their use of healthcare resources during
the previous (observational period) year. These
questions served as a quality check of the medical
record entries and elicited any missing data.
Costs related to direct healthcare resources were
obtained from the OBLIKUE database of Spanish
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Fig. 1. Study design. eCRF =electronic case report form.
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healthcare costs for the year 2008.[28] Unit cost of
medications for the treatment of type 2 diabetes
and related co-morbidities were obtained from
the BOT database (General Council of Official
Colleges of Pharmacists of Spain).[29] In addition,
patients completed two HR-QOL questionnaires
at the study visit: the EuroQol-5D (EQ-5D) health
questionnaire[30] and a Spanish version of the
Diabetes Quality of Life (DQOL) questionnaire.[31]
Statistical Analysis
The study was planned to include 779 patients,
allowing the detection of a low correlation be-
tween BMI and direct diabetes costs (0.1) at a
significance level of 0.05 and with a statistical
power of 0.80. Based on the change in BMI
during the study reference period, the patients
were classified as BMI gainers (change in BMI
>0) and non-BMI gainers (patients who experi-
enced either a loss or no change in BMI). The
demographic and clinical characteristics for these
two subgroups were assessed using descriptive
summary statistics. Means and standard devia-
tions (SDs) were calculated for continuous vari-
ables. Absolute frequencies and percentages were
calculated for categorical variables. All percen-
tage calculations were based on the number of
patients studied. Univariate comparisons were
performed between BMI gainers and non-BMI
gainers: Chi-square tests or the Cochran-Armitage
trend test were used to compare categorical vari-
ables. Wilcoxon tests and analyses of covariance
were used to compare continuous variables.
Mean, SD and median for direct 1-year health-
care costs in the BMI-gainer and non-BMI-gainer
subgroups were also calculated and compared de-
scriptively using Wilcoxon tests. In addition, 95%
confidence intervals for mean cost were derived via
bootstrapping.
Generalized linear mixed models (GLMMs)
provide a flexible way to model production traits
that do not satisfy the assumptions of an ordinary
least-square regression, e.g. cost data.[32] There-
fore, the economic impact of BMI change on type
2 diabetes total direct costs was assessed using
three GLMMs with a log link function and
gamma error distribution. The estimated regres-
sion coefficient was transformed to euros and
expressed as percentage change in the total direct
cost for each unit (1 kg/m2) increase or decrease
in BMI.
In GLMM model 1 (one-slope model), the
direct cost of diabetes (absolute values) was
analysed according to the BMI at 12 months
prior to the study visit, including the cost as de-
pendent variable and the BMI as independent
variable. This allowed the estimation of the im-
pact that an increase of one BMI unit had on the
direct cost per patient. In GLMM model 2 (two-
slope model), the direct cost of diabetes was
analysed according to the change in BMI from
baseline to 12 months during the study reference
period (i.e. gain vs no gain), and the interaction
between both variables. Statistically significant
differences in cost between BMI gainers and non-
BMI gainers could be detected owing to the ad-
dition of the interaction term in the model. This
analysis resulted in separate slope estimates for
BMI gainers and non-BMI gainers.
Based on GLMM model 2, GLMM model 3
(four-slope model) allowed the study of statisti-
cally significant differences in direct diabetes
costs among BMI gainers and non-BMI gainers
according to obesity status, i.e. in patients de-
fined according to the World Health Organiza-
tion[13] as obese (BMI ‡30 kg/m2) or non-obese
(BMI <30 kg/m2) at the study visit. Change in
BMI during the study reference period, obesity
status at the study visit and the corresponding
interaction terms were included as independent
regression variables. This analysis resulted in se-
parate slope estimates at baseline for (i) BMI
gainer, obese patients; (ii) BMI gainer, non-obese
patients; (iii) non-BMI gainer, obese patients;
and (iv) non-BMI gainer, non-obese patients.
Variables that could potentially confound the
observed associations were included in all these
models as independent regression variables.
These included baseline sociodemographic and
clinical variables, diabetes treatment informa-
tion, DQOL, EQ-5D, work productivity, and
diabetes-related microvascular and macrovas-
cular complications. For all three GLMM mod-
els, the selection process was as follows. First,
individual GLMMs were performed (with direct
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cost as dependent variable and each variable as
independent regression variable) in order to de-
tect factors related to the total direct cost. In a
second step, the variables that were found to be
significant in the individual models were then
used to build the multivariate model. Results re-
garding the first step of the multivariate model
build are provided in table S1 of the Supple-
mental Digital Content, http://links.adisonline.
com/APZ/A62.Missing values were not imputed.
These three multivariate GLMMs were also rep-
licated using weight instead of BMI.
Statistical significance was evaluated at the
0.05 level. Statistical Analysis System software
version 8 (SAS Institute, Inc., Cary,NC,USA)was
used for all analyses.
Results
The study was conducted in Spain by 80
investigators (25 primary care physicians, 27 endo-
crinologists and 28 specialists in internal med-
icine) at 80 sites located either in hospitals or
private practices (these data refer only to sites
and investigators who contributed the 757 pa-
tients entered in the study). A total of 757 patients
entered the study between March and November
2008, 738 of whom were eligible for analysis. Of
the eligible patients, 304 (41.2%) were categorized
as BMI gainers and 434 (58.8%) as non-BMI
gainers. Among the non-BMI gainers, 385 (52.2%
of the total eligible population) showed BMI loss
and 49 (6.6%) showed no BMI change.
Patient Characteristics
Overall, the mean age was 66 years and 54.2%
of the 738 patients were males (table I). Most
patients were Caucasian (97.0%), 71.8% were
educated to primary level at most, 42.7% were
retired, and 59.8% had never smoked. The number
of patients unable to work because of diabetes was
relatively low (1.9%), so was the number of patients
unable to work due to other reasons (BMI gainers:
4.9% and non-BMI gainers: 2.1%). The mean
time since diabetes diagnosis was statistically
significantly higher in BMI gainers (12 years)
than non-BMI gainers (10 years) [p < 0.01]. Most
patients had been on non-insulin treatment only
during the last 12 months (BMI gainers 53.3%;
non-BMI gainers 67.7%). A quarter (25.5%) had
used both insulin and non-insulin treatment
(BMI gainers 32.9% and non-BMI gainers
20.3%) and 8.9% (BMI gainers 10.9%, non-BMI
gainers 7.6%) had used only insulin. Overall,
46 patients (6.2%) initiated insulin during the
12-month observational period. Regarding the
use of metformin, 160 (52.6%) of the BMI gainers
and 294 (67.4%) of non-BMI gainers had used
metformin alone or in combination with insulin
or other oral antidiabetic drugs (sulphonylureas
and thiazolidinediones).
BMI gainers and non-BMI gainers had a sim-
ilar mean waist circumference 12 months prior to
baseline, but BMI gainers had a statistically sig-
nificantly greater waist circumference than non-
BMI gainers at the study visit (p< 0.001) [table II].
BMI gainers also had significantly higher mean
HbA1c and FPG values than non-BMI gainers at
the study visit (both p < 0.001). With the excep-
tion of triglycerides (p = 0.008), no statistically
significant differences were observed for lipids
and blood pressure at the study visit (table II).
Direct Healthcare Costs
During the study reference period, the average
1-year total direct healthcare cost for the entire
study population was h2336.67 per patient
(median h1683.27). This cost comprised a phar-
macy cost of h1512.48 (median h1192.40) and a
medical cost of h828.29 (median h242.56) [table III].
The mean pharmacy cost was higher than the
medical cost in both the BMI gainers and the non-
BMI gainers. The bulk of the pharmacy costs in
both groups (approximately 75%) was due to
costs of blood glucose monitoring and diabetes-
related medication. If we compare between
groups, the mean pharmacy cost was significantly
higher (p = 0.0054) in the BMI gainers than in the
non-BMI gainers. This finding was attributable
to significantly higher costs for insulin (p < 0.001)
and for blood glucose monitoring (p < 0.001)
among BMI gainers. The mean medical cost was
lower in the BMI gainers (h784 vs h859), but the
difference was not statistically significant.
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Table I. Sociodemographic characteristics (at the study visit) of the study population by BMI cohorta,b
Characteristic BMI gainers
(n =304)
Non-BMI gainers
(n= 434)
Total
(N = 738)
Mean age, years (SD) 65 (11) 66 (11) 66 (11)
Gender, n (%)
Male 161 (53.0) 239 (55.1) 400 (54.2)
Female 143 (47.0) 195 (44.9) 338 (45.8)
Race, n (%)
Caucasian 295 (97.0) 421 (97.0) 716 (97.0)
Hispanic 8 (2.6) 11 (2.5) 19 (2.6)
Others 1 (0.3) 2 (0.5) 3 (0.4)
Mean time since diagnosis, years (SD)c 12 (8) 10 (7) 11 (8)
Has the patient ever smoked? n (%)
No 169 (55.6) 272 (62.7) 441 (59.8)
Yes 135 (44.4) 162 (37.3) 297 (40.2)
Is the patient currently smoking? n (%)d
No 94 (69.6) 119 (73.5) 213 (71.7)
Yes 41 (30.4) 43 (26.5) 84 (28.3)
Number of cigarettes per day (last 12 months), n (SD)d 3.9 (7.5) 4.4 (8.5) 4.2 (8.0)
Environment, n (%)
Urban 220 (72.4) 290 (66.8) 510 (69.1)
Rural 43 (14.1) 82 (18.9) 125 (16.9)
Semi-rural 41 (13.5) 62 (14.3) 103 (14.0)
Education, n (%)e
Illiterate/no formal education 57 (18.8) 81 (18.7) 138 (18.7)
Primary 176 (57.9) 216 (49.8) 392 (53.1)
Secondary 54 (17.8) 96 (22.1) 150 (20.3)
University 16 (5.3) 40 (9.2) 56 (7.6)
Missing 1 (0.3) 1 (0.2) 2 (0.3)
Occupation (last 3 months), n (%)f
Retired 124 (40.8) 191 (44.0) 315 (42.7)
Fulltime employed 73 (24.0) 115 (26.5) 188 (25.5)
House-keeping 77 (25.3) 91 (21.0) 168 (22.8)
Unable to work for reasons not related to diabetes 15 (4.9) 9 (2.1) 24 (3.3)
Unemployed 6 (2.0) 12 (2.8) 18 (2.4)
Unable to work because of diabetes 6 (2.0) 8 (1.8) 14 (1.9)
Student 2 (0.7) 4 (0.9) 6 (0.8)
Other 1 (0.3) 4 (0.9) 5 (0.7)
Diabetes treatment (last 12 months), n (%)g
Non-insulin only 162 (53.3) 294 (67.7) 456 (61.8)
Both insulin and non-insulin 100 (32.9) 88 (20.3) 188 (25.5)
Insulin only 33 (10.9) 33 (7.6) 66 (8.9)
None 9 (3.0) 19 (4.4) 28 (3.8)
Non-insulin treatment (12 months prior to study visit), n (%)
Metformin only 123 (40.5) 181 (41.7) 304 (41.2)
Sulphonylurea only 34 (11.2) 33 (7.6) 67 (9.1)
Continued next page
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Healthcare Costs and BMI Change
Three GLMMs were used to explore the as-
sociation of diabetes-related healthcare costs
with BMI change during the 12-month study
reference period. Due to missing values, only
data of 517 patients could be used (BMI gainers:
198 patients; non-BMI gainers: 319 patients).
These patients had a mean age of 65 years and
57.6% were male. The mean time since diagnosis
of diabetes was 11 years for BMI gainers and
9 years for non-BMI gainers (p = 0.079). The
majority of patients had never smoked (59.0%).
Most patients had been on non-insulin treatment
only during the last 12 months (BMI gainers
57.6%; non-BMI gainers 72.4%). Overall, 22.8%
had used both insulin and non-insulin treatment
(BMI gainers 31.3% and non-BMI gainers
17.6%) and 6.2% (BMI gainers 7.6%; non-BMI
gainers 5.3%) had used only insulin. Regarding
the use of metformin, 112 (56.6%) of the BMI
gainers and 177 (55.5%) of non-BMI gainers had
used metformin alone or in combination.
In model 1 (one-slope model), a unit gain in
BMI was statistically significantly (p < 0.001)
associated with an increase of 2.4% in total direct
costs (figure 2 and table IV). When the effects of
BMI gain and no BMI gain during the study
reference period were assessed separately for
BMI gainers and non-BMI gainers (model 2, two-
slope model), a one-unit change in BMI was
associated in BMI gainers with a 20.0% increase
in costs, but in non-BMI gainers with an 8.0%
decrease in costs (p < 0.01 for the comparison of
subgroups, table IV).
Model 3 (four-slope model) examined the as-
sociation of BMI change with 1-year direct costs
during the study reference period according to
patients’ obesity status at the study visit. Among
non-BMI gainers, a one-unit decrease in BMI
was associated with a decrease of 9.4% in total
direct costs in obese patients and a decrease of
2.7% in non-obese patients (table IV). Among
BMI gainers, a one-unit increase in BMI was
associated with an increase of 19.6% and 18.7% in
total direct costs in obese and non-obese patients,
respectively.
Similar patterns of results were obtained when
weight, instead of BMI, was applied in the three
GLMM models. In model 1, a gain of 1 kg was
significantly (p= 0.003) associated with an increase
Table I. Contd
Characteristic BMI gainers
(n =304)
Non-BMI gainers
(n= 434)
Total
(N = 738)
TZDs only 6 (2.0) 17 (3.9) 23 (3.1)
Combination of 2 oral antidiabetics 32 (10.5) 55 (12.7) 87 (11.8)
Combination of 3 oral antidiabetics 8 (2.6) 14 (3.2) 22 (3.0)
Other 36 (11.8) 49 (11.3) 85 (11.5)
Type of BG monitoring during 12 months prior to study visit, n (%)
None 79 (26.0) 163 (37.6) 242 (32.8)
Urine test strips only 0 (0.0) 3 (0.7) 3 (0.4)
Blood glucose monitoring strips only 218 (71.7) 260 (59.9) 478 (64.8)
Both urine and blood glucose strips 7 (2.3) 8 (1.8) 15 (2.0)
a BMI gainers: patients whose BMI increased during the 12 months prior to the study visit. Non-BMI gainers: patients who experienced no
gain in BMI, i.e. either a loss (n= 385) or no change (n= 49) during the 12 months prior to the study visit.
b Continuous data are means. Wilcoxon tests were used for statistical comparisons of continuous variables. Chi-square tests and the
Cochran-Armitage trend test (for Education only, excluding missing values) were used for statistical comparisons of categorical variables.
c p< 0.01 comparing BMI gainers and non-BMI gainers.
d Only patients who have ever smoked = 100%.
e p <0.05 comparing BMI gainers and non-BMI gainers taking into account all categories under ‘Education’.
f No statistical comparison performed.
g p<0.001 comparing BMI gainers and non-BMI gainers, taking into account all categories under ‘Diabetes treatment during the last 12months’.
BG = blood glucose; BMI = body mass index; n =number of patients; N = total population size; TZD = thiazolidinediones.
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of 0.8% in total direct costs. When weight changes
during the study reference period were modelled
separately for weight gainers (patients who
experienced gain in weight) and non-weight gai-
ners (patients who experienced either loss or no
change in weight), every unit gain in weight was
associated with a 7.6% increase in total direct
costs, while a loss of 1 kg was associated with
a 2.8% decrease in total direct costs (model 2).
According to model 3, for the non-weight gainers,
the economic benefit association with a reduction
in weight was greater in obese patients (3.4% de-
crease in total direct costs per 1 kg of weight lost)
than in non-obese patients (0.7% decrease per
1 kg of weight lost). Among weight gainers, a 1 kg
increase in weight was associated with an increase
of 7.8% and 6.4% in total direct costs in obese and
non-obese patients, respectively.
Discussion
Obesity is a significant determinant of health-
care costs, since it predisposes patients to chronic
and costly medical conditions such as type 2
diabetes.[33] The observational ECOBIM study
was designed to assess the relationship between
1-year direct healthcare costs and BMI change in
patients with type 2 diabetes in Spain. Its results
have important implications for clinicians in-
volved in the management of patients with type 2
diabetes and the associated complications and
co-morbidities.
Mean pharmacy costs over 1 year were almost
twice the medical costs in both the BMI-gainers
and the non-BMI-gainers groups within the
ECOBIM population, owing mainly to costs of
blood glucose testing and diabetes-related med-
ication. This is in line with a previous study on the
economic costs associated with type 2 diabetes in
Spain.[8] The authors reported that medications
were the major cost driver (42% of annual direct
healthcare costs per patient), with non-diabetes-
related drugs accounting for the main proportion
in the overall pharmacological costs (76%). Fo-
cusing on the difference between both groups in
the pharmacy costs, the higher percentage of
Table II. Clinical characteristics of the study population by BMI cohorta
Characteristic BMI gainers [n =304]
Mean (SD)
Non-BMI gainers [n =434]
Mean (SD)
p-Valueb Total [N= 738]
Mean (SD)
Prior
12 months
Study visit Prior
12 months
Study visit Prior
12 months
Study
visit
Prior
12 months
Study visit
HbA1c, % 7.4 (1.8) 7.3 (1.6) 7.2 (1.6) 6.8 (1.7) NA <0.001 7.3 (1.7) 7.0 (1.7)
FPG, mg/dL 149.8 (50.9) 147.5 (50.2) 143.3 (43.6) 133.1 (41.9) NA <0.001 146.0 (46.8) 139.0 (46.0)
Weight, kg 81.2 (15.6) 83.5 (16.0) 81.7 (13.4) 79.2 (13.0) 0.413 NAc 81.5 (14.3) 81.0 (14.5)
BMI, kg/m2 30.9 (5.7) 31.8 (5.8) 30.7 (4.8) 29.7 (4.6) 0.789 NAc 30.8 (5.2) 30.6 (5.2)
Waist circumference, cm 102.6 (13.6) 104.3 (13.8) 102.4 (12.2) 100.8 (11.8) NA <0.001 102.5 (12.8) 102.3 (12.7)
HDL-cholesterol, mg/dL 49.2 (13.2) 48.2 (12.7) 48.9 (13.0) 48.3 (13.4) NA 0.954 49.0 (13.1) 48.3 (13.1)
LDL-cholesterol, mg/dL 109.7 (30.5) 105.1 (31.1) 117.5 (35.0) 107.0 (32.6) NA 0.232 114.3 (33.4) 106.2 (32.0)
Total cholesterol, mg/dL 188.6 (43.1) 180.0 (37.9) 194.0 (40.7) 179.1 (37.6) NA 0.102 191.8 (41.8) 179.5 (37.7)
Triglycerides, mg/dL 141.8 (92.0) 142.4 (83.3) 149.8 (94.5) 135.0 (71.6) NA 0.008 146.6 (93.5) 138.0 (76.7)
Systolic BP, mmHg 136.9 (15.5) 137.3 (18.4) 137.0 (16.3) 136.0 (14.4) NA 0.180 137.0 (16.0) 136.5 (16.2)
Diastolic BP, mmHg 77.9 (10.1) 77.5 (11.1) 78.4 (9.9) 77.4 (9.7) NA 0.562 78.2 (10.0) 77.4 (10.3)
a BMI gainers: patients whose BMI increased during the 12 months prior to the study visit. Non-BMI gainers: patients who experienced no
gain in BMI, i.e. either a loss (n= 385) or no change (n= 49) during the 12 months prior to the study visit.
b For all variables except weight and BMI, comparisons were performed by analyses of covariance with the value at study visit as the
dependant variable, the BMI cohort as independent factor and the value at 12 months prior to the study visit as covariable.
c Wilcoxon tests were used for the statistical comparisons of weight and BMI. No analyses of covariance were performed as these variables
were included in the definition of BMI cohorts.
BMI = body mass index; BP =blood pressure; FPG = fasting plasma glucose; HbA1c= glycosylated haemoglobin A1c; HDL =high-density
lipoprotein; LDL = low-density lipoprotein; N = total population size; NA = not applicable.
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patients with insulin treatment among BMI
gainers (44% vs 28%) could explain the approxi-
mately 1.5-fold higher costs for insulin treatment
and blood glucose monitoring in this cohort. In
contrast to the pharmacy costs, the mean medical
cost in ECOBIM was approximately 9% lower in
BMI gainers than in non-BMI gainers. This dif-
ference was not statistically significant and its
importance is unclear. Mean hospitalization
costs were statistically significantly higher in non-
BMI gainers. As the variability of hospitalization
costs was also large in this group compared with
the BMI gainers, mean costs for non-BMI gainers
may have been influenced by some patients with
very long stays at the hospital and therefore very
high individual costs. Although there is some
evidence for a reduction of healthcare costs in
patients at very high BMI levels (>36 kg/m2), in-
creasing body mass is directly associated with an
increasing use of healthcare services over the
range of BMI observed in the ECOBIM study.[34]
Overall, among ECOBIM participants, a one-
unit gain in BMI was statistically significantly
associated with a 2.4% increase in total direct
costs (p< 0.001), a one-unit change in BMI gainers
was associated with a 20.0% increase in total
costs, while in non-BMI gainers, a one-unit de-
crease in BMI was associated with an 8.0% de-
crease in total costs (p < 0.01 for the comparison
between BMI/non-BMI gainers). The estimated
Table III. BMI changes and direct healthcare costs among BMI gainers and non-BMI gainersa,b
Variable BMI gainers
(n= 304)
Non-BMI gainers
(n= 434)
p-Value
Baseline BMI, kg/m2 31.81 (5.84) 29.73 (4.58) <0.001
Absolute BMI change, kg/m2 0.87 (0.72) –0.96 (1.12)
1-year direct healthcare costs during study reference period, h
Total 2452.62 (2214.87)
[2235.43, 2734.26]
2255.45c (2387.36)
[2047.16, 2512.44]
0.053
Pharmacy costs 1668.67 (1301.88)
[1531.60, 1815.00]
1402.57c (1257.51)
[1285.28, 1541.59]
0.005
Insulin treatment 229.63 (342.60)
[195.87, 271.46]
143.73 (293.33)
[116.87, 172.88]
<0.001
Non-insulin treatment 196.25 (296.36)
[168.58, 230.61]
192.96 (274.23)
[168.51, 219.51]
0.571
Diabetes-related medicationd 552.99 (620.47)
[486.90, 627.46]
562.72 (858.68)
[491.72, 667.45]
0.317
Blood glucose monitoring 689.80 (842.19)
[598.62, 795.06]
496.70 (672.71)
[440.13, 567.31]
0.001
Medical costs 783.95 (1717.41)
[636.11, 1040.88]
859.35c (1776.29)
[723.29, 1061.47]
0.414
Healthcare professional visits 259.99 (438.64)
[218.75, 319.92]
230.10 (287.38)
[205.28, 258.09]
0.828
Additional healthcare visits 87.58 (154.41)
[74.53, 108.03]
87.09 (127.68)
[76.17, 100.16]
0.811
Hospitalization costs 436.38 (1520.18)
[303.93, 653.86]
542.16 (1612.62)
[419.91, 738.92]
0.036
a Non-BMI gainers: patients who experienced no gain in BMI, i.e. either a loss (n =385) or no change (n =49) during the 12months prior to the
study visit.
b All values are mean (SD). In addition, 95% confidence intervals for the mean costs generated using bootstrapping methods are provided.
Wilcoxon tests were used for statistical comparisons of continuous variables.
c For non-BMI gainers, missing values account for the difference between the total healthcare cost and the sum of medical and pharmacy
costs.
d Diabetes-related medication: other than insulin and OADs.
BMI = body mass index; OAD = oral antidiabetic medication.
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economic benefit of BMI reduction was ap-
proximately 3-fold greater in obese patients than
in non-obese patients. These results are consistent
with previous findings. Over a decade ago, it
was estimated that an increase of one BMI unit
among the general population in the US was
associated with a 7% increase in total healthcare
expenditure in males and a 16% increase in
females. This increase in costs was attributed to
the increased risk of chronic illnesses such as type
2 diabetes, although no significant relationship
was observed when patients with specific illnesses
were analysed.[34] Another study that combined
information from patient surveys, medical chart
reviews and health insurance claims estimated
that, among individuals with type 2 diabetes,
every unit increase in BMI (over 30 kg/m2) in-
creased annual direct medical costs by 1%.[35]
More recently, Yu et al.[33] analysed healthcare
database information in the US and found that
the mean total healthcare cost over 12 months
was approximately 30% higher among patients
with type 2 diabetes who gained weight over a
6-month observation period than among those
who did not gain weight (p = 0.046). Diabetes-
related costs were 14% higher among weight
gainers than non-weight gainers (p = 0.006). Ac-
cording to a GLMM analysis, a 1% change in
weight was associated with an approximately 3%
change in total diabetes-related costs (p < 0.01).
When modelled separately, weight loss was sig-
nificantly associated with a reduction in costs,
while weight gain was not statistically signif-
icantly associated with an increase. As in the
present study, the benefit of weight loss was most
pronounced in obese patients, in whom a 1% re-
duction in weight was associated with a 6.7%
decrease in diabetes-related costs (p < 0.01).[34]
Further evidence supports the conclusion that
weight loss is associated with a reduction of eco-
nomic costs among obese patients with type 2
diabetes. A small, prospective study assessed the
effect of an intensive, 12-week weight reduction
programme on prescription costs in obese
patients with type 2 diabetes (n = 40).[36] The
mean observed weight loss of 14.8% at the end of
the programme was associated with a 49% re-
duction in prescription costs at 1 year. Data from
a modelling study in the general population also
suggest that a weight loss of 10% may yield sub-
stantial long-term economic benefits, mostly
owing to reductions in the costs of type 2 dia-
betes, coronary heart disease and hyperten-
sion.[37] Lifetime economic costs were reduced by
up to $US5300 (year 1996 values) with the
greatest benefits in patients at the highest initial
BMI levels. Results obtained from a recent study
that analysed the clinical and economic benefits
of bariatric surgery in obese (BMI ‡35 kg/m2)
diabetic patients support the conclusion made in
this study.[21]
The present study has certain limitations.
First, the economic benefit associated with weight
loss was measured over a short-term period of
12 months. Further data are required on the ef-
fect of weight and/or BMI change on long-term
direct costs in patients with type 2 diabetes, to-
gether with the factors that underlie variations in
weight. Second, the measurement of BMI change
in parallel with 1-year direct costs may confound
the interpretation of the relationship between
these variables because events such as hospitali-
zation and emergency room visits could con-
tribute to a change in BMI or weight, as well as to
the related medical cost. Third, because of bu-
reaucratic difficulties, centres across all Spanish
regions but two (Paı´s Vasco and Navarra) parti-
cipated in the study; these two regions represent
around 6.1%[38] of the national population.
BMI 12 months prior to study visit [kg/m2]
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Fig. 2. Total direct costs relative to body mass index (BMI) at
12 months prior to the study visit. This figure is a visualization of
a simplified model 1, with BMI at 12 months prior to study visit as
the only independent factor.
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Fourth, due to the observational nature of the
study, the data registry started after patients had
signed the informed consent, therefore patient
response rate has not been collected. Fifth, be-
cause of the way data have been collected, it was
not possible to separate cost into that attributable
to diabetes, diabetic complications and co-
morbidities. Sixth, due to missing values, only
data of 517 patients could be used; despite the
fact that no obvious differences were observed
between these 517 patients and the overall 738,
this could nevertheless have weakened the gen-
eralization of the findings. Seventh, the study
cannot explain the possible reasons for BMI or
weight change during the reference period. Many
factors could have contributed to the observed
changes, including diabetes- and non-diabetes-
related medications, diet, physical exercise, disease
severity, and other related co-morbidities. In the
future, the economic consequences of BMI or
weight change should ideally be studied in various
subgroups categorized by gender, age, duration
of diabetes, diabetes-related complications,
diabetes treatment and selected co-morbidities.
Lastly, data on healthcare resource utilization
were collected retrospectively and therefore may
not be complete. An attempt was made to over-
come this problem by asking patients to complete
this information, where necessary, at the study
visit.
Conclusions
An increase in BMI among patients with type
2 diabetes in Spain was associated with increased
1-year direct healthcare costs. A reduction in
BMI was associated with appreciable short-term
economic benefits, especially in obese patients.
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